Hypertension Clinical Trial
Official title:
An Open-label, Prospective, Controlled Clinical Trial on Effects and Safety of Adrenal Artery Ablation (Triple A) for Primary Aldosteronism
Verified date | July 2019 |
Source | Third Military Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary aldosteronism (PA) is one of the most common cause of endocrine and resistant
hypertension. Current studies have shown that the activation of the
renin-angiotensin-aldosterone system (RAAS) and the increased sympathetic nerve activity in
the central or local tissue are the key mechanisms of high blood pressure and its organ
damages.
The classical method for diagnosis of primary aldosteronism depends on the detection of
peripheral venous blood aldosterone level, which is incapable of accurate positioning
diagnosis. On the other hand, the current guidelines recommend that surgery and aldosterone
receptor inhibitors were the only treatment for primary aldosteronism. However, only about
35% of aldosterone tumors and a small part of unilateral adrenal hyperplasia can be treated
by surgery. More than 60% of idiopathic aldosteronism and bilateral adrenal hyperplasia need
long-term drug therapy. However, long-term aldosterone inhibitor treatment may also cause
hyperkalemia, male breast hyperplasia, female hirsutism and other adverse reactions.
Therefore, the investigators proposed that endovascular chemical partial ablation of the
adrenal gland can lower the aldosterone level, reduce the blood pressure and recover the
potassium metabolism balance. In order to confirm the above effects, the investigators
conduct an open, prospective, positive controlled study in patients with primary
aldosteronism patients (including aldosterone, idiopathic aldosteronism and adrenal
hyperplasia). The effects on blood pressure, blood electrolytes, adrenal hormones, metabolic
indexes, target organ damages were observed to explore the efficacy and safety of the
endovascular ablation of the adrenal gland in the treatment of primary aldosteronism.
Status | Completed |
Enrollment | 66 |
Est. completion date | June 30, 2019 |
Est. primary completion date | December 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Primary Aldosteronis diagnosed by increased Renin ratio (ARR) and serum aldosterone levels =15 ng / dl, and confirmed by saline injection test or captopril inhibition test. - Idiopathic aldosteronism, bilateral adrenal hyperplasia, and unilateral adrenal hyperplasia with no superior secretion confirmed with adrenal CT and adrenal venous blood (AVS). - The patients was diagnosed with aldosteronoma or unilateral adrenal hyperplasia but refused to surgical excision. - Signed informed consent and agreed to participate in this study. Exclusion Criteria: - Aldosterone cancer. - Hyperkalemia. - Renal failure or the following history of nephropathy: serum creatinine 1.5 times higher than the upper limit; dialysis history; or nephrotic syndrome. - Secondary hypertension except the primary aldosteronism. - Adrenergic insufficiency. - Heart failure with NYHA grade ?-? grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events. - Acute infections, tumors and severe arrhythmias, psychiatric disorders, drugs or alcohol addicts. - Liver dysfunction or the following history of liver disease: AST or ALT 2 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history. - Coagulation dysfunction. - Pregnant women or lactating women. - Participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial. - Any surgical or medical condition which can significantly alter the absorption, distribution, metabolism, or excretion of any study drug. - Allergy or any contraindications for the study drugs, contrast agents and alcohol. - Refused to sign informed consent |
Country | Name | City | State |
---|---|---|---|
China | The third hospital affiliated to the Third Military Medical University | Chongqing | Chongqing |
Lead Sponsor | Collaborator |
---|---|
Third Military Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change of testosterone and estrogen levels | Change of testosterone and estrogen levels compared with baseline, and between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Other | Change of 24-h urine microalbumin, microalbumin/creatinine ratio | Change of 24-h urine microalbumin, microalbumin/creatinine ratio compared with baseline, and between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Other | Change of parameters assessed by echocardiography (IVSd?IVSs?LVPWd, LVPWs, LVEDD, LVEF, LVM) | Change of parameters assessed by echocardiography (IVSd?IVSs?LVPWd, LVPWs, LVEDD, LVEF, LVM) compared with baseline, and between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Other | Change of carotid intima-media thickness assessed by carotid ultrasound | Change of carotid intima-media thickness(CIMT) assessed by carotid ultrasound compared with baseline, and between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Other | Change of electrocardiogram manifestations | Change of electrocardiogram manifestations(heart rhythms, heart rates and arrhythmia ) compared with baseline, and between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Primary | Change of 24-h average systolic blood pressure compared with the baseline | Change of 24-h average systolic blood pressure compared with the baseline at the end of the study (24 weeks) in the intervention group. | 24 weeks | |
Secondary | Change of 24-h average systolic blood pressure between two groups | Change of 24-h average systolic blood pressure between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Secondary | Change of anti-hypertensive regimen between two groups | Change of number, classes, and combinations of classes of antihypertensive drugs between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Secondary | Change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure between two groups | Change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Secondary | Change of office systolic and diastolic pressure between two groups | Change of office systolic and diastolic pressure between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Secondary | Change of blood electrolytes(serum potassium and natrium in mmol/L) | Change of blood electrolytes(serum potassium and natrium in mmol/L) compared with baseline, and between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Secondary | Change of plasma aldosterone and 24-h urine aldosterone | Change of plasma aldosterone and 24-h urine aldosterone compared with baseline, and between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Secondary | Change of plasma renin | Change of plasma renin compared with baseline, and between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Secondary | Change of plasma cortisol and 24-h urine cortisol | Change of plasma cortisol and 24-h urine cortisol compared with baseline, and between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Secondary | Change of liver enzymes (ALT, AST) | Change of liver enzymes (ALT, AST) compared with baseline, and between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Secondary | Change of serum creatinine | Change of serum creatinine compared with baseline, and between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Secondary | Change of fasting blood glucose | Change of fasting blood glucose in mmol/L compared with baseline, and between the intervention and control group at the end of the study (24 weeks) | 24 weeks | |
Secondary | Change of lipids profiles (TC, HDL-C, LDL-C, TG) in mmol/L | Change of lipids profiles (Total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride) in mmol/L compared with baseline, and between the intervention and control group at the end of the study (24 weeks) | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |